Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.

Biomed Pharmacother

Key Laboratory of Pathobiology, Ministry of Education, Norman Bethune College of Medicine, Jilin University, 126 Xin-Min Ave., Changchun, Jilin Province, 130021, China. Electronic address:

Published: October 2020

Rapidly increasing usages of immune checkpoint therapy for cancer treatment, particularly monoclonal antibodies that target programmed cell death-1 (PD-1) and its ligand PD-L1, have been achieved due to startling durable therapeutic efficacy with limited toxicity. The therapeutics significantly prolonged the overall survival and progression free survival of patients across multiple cancer types. However, the objective response rate of patients receiving this kind of treatment is substantially low. Therefore, it is of great importance to exploit reliable biomarkers that can robustly predict the therapeutic effects. Several biomarkers have been characterized for the selection of patients, which is mainly based on immunological and genetic criteria. Herein, we focus on the current progress regarding the biomarkers for anti-PD-1/PD-L1 therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2020.110621DOI Listing

Publication Analysis

Top Keywords

immune checkpoint
8
checkpoint therapy
8
programmed death
8
biomarkers
4
biomarkers immune
4
therapy targeting
4
targeting programmed
4
death programmed
4
death ligand
4
ligand rapidly
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!